Halozyme Therapeutics (HALO) announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European Commission approval for an indication extension of DARZALEX, or daratumumab, subcutaneous co-formulated with Halozyme's ENHANZE in the frontline setting. The approval is for daratumumab SC in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.